Abstract:Abstract Psoriasis is a chronic, systemic, immune-mediated disease that is associated with severe comorbidities including depression, psoriatic arthritis and cardiovascular disease. As a result, psoriasis impacts on patient wellbeing and quality of life. Biologic therapies are highly effective for psoriasis; however, 11–35% of patients do not respond to their first treatment within the first year. Bimekizumab is a humanized monoclonal antibody that neutralizes the activity of the proinflammatory cytokines interleukin-17A and interleukin-17F, which are pivotal in developing psoriasis. This study assessed changes in disease severity and health-related quality of life in patients with psoriasis who were treated with bimekizumab in routine clinical practice. This cross-sectional study included adult patients with psoriasis who were attending routine clinical practice visits at five hospitals in the UK. Patients may have received prior therapy for psoriasis, and all were subsequently treated with bimekizumab. In total, 66 patients were included in the study; 35 (53%) were women, the mean age was 47.1 years (SD 15.5), the mean duration of disease was 19.6 years (SD 9.9) and the mean body mass index was 31.2 kg m−2 (SD 6.4). At baseline, the majority of patients (38 of 62, 61%) had extensive or widespread psoriasis, and 23 of 58 (40%) had psoriatic arthritis. Seven patients (11%) were treatment naive to biologic therapy, 55 of 65 (85%) had not responded to previous biologic therapy, and 43 of 65 (66%) had received adalimumab. After initiation of bimekizumab, there was a substantial improvement in disease severity at week 16. The mean Psoriasis Area and Severity Index (PASI) at baseline was 17.1, and no patients had a score of 0; the mean PASI at week 16 was 1.7, and 20 of 52 patients (38%) had a score of 0. This improvement in PASI was accompanied by an improvement in quality of life (Table). Qualitative data reported by patients indicated that treatment with bimekizumab improved their daily lives and decreased psychological stresses. In this study, bimekizumab reduced the severity of psoriasis and improved patients’ quality of life and overall wellbeing. These results indicate that bimekizumab should be considered for the treatment of patients with severe psoriasis where rapid and significant clearance of psoriasis is clinically appropriate, including treatment-naive patients and those resistant to previous biologic therapy. Medical writing support was funded by UCB; the study was conducted independently of the sponsor.ParameterPatientsBaselineWeek 16PASI scoreaMean (SD)17.1 (7.3)1.7 (4.1)Median (range)14.8 (4–43)0.5 (0–27)DLQI scorebMean (SD)20.2 (6.1)3.6 (5.4)Median (range)20.0 (10–33)1.0 (0–25)Psoriasis Area and Severity Index: baseline, n = 65; week 16, n = 52. Dermatology Life Quality Index: baseline, n = 64; week 16, n = 51.

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

Bimekizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: a Meta-Analysis of Randomized Clinical Trials

P106 Clinical outcomes and quality of life in a cross-sectional study of patients with moderate-to-severe psoriasis treated with bimekizumab in routine clinical practice

Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review

Bimekizumab for the treatment of psoriasis

Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study

Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials

Bimekizumab: A Review in Psoriatic Arthritis

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

BIMZELX® (Bimekizumab-bkzx) Injection, for Subcutaneous Use

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Real‐world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single‐center retrospective study

Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies